|
|
Volumn 345, Issue 8955, 1995, Pages 952-955
|
|
Safety and activity of saquinavir in HIV infection
a
c
Roche Products Ltd
*
(France)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ISOQUINOLINE DERIVATIVE;
QUINOLINE DERIVATIVE;
SAQUINAVIR;
ANTIVIRUS AGENT;
CD4 ANTIGEN;
INDINAVIR;
PROTEINASE INHIBITOR;
VIRUS DNA;
VIRUS ENZYME;
VIRUS RNA;
ARTICLE;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DOSE RESPONSE;
DOUBLE BLIND PROCEDURE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
IMMUNOLOGY;
ISOLATION AND PURIFICATION;
MALE;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
VIROLOGY;
ANTIVIRAL ACTIVITY;
CLINICAL ARTICLE;
DNA DETERMINATION;
DRUG BIOAVAILABILITY;
DRUG MECHANISM;
DRUG TARGETING;
ENZYME INHIBITION;
HEADACHE;
LYMPHOCYTE COUNT;
MONONUCLEAR CELL;
ORAL DRUG ADMINISTRATION;
POLYMERASE CHAIN REACTION;
PRIORITY JOURNAL;
RNA ANALYSIS;
VIREMIA;
VIRUS CULTURE;
VIRUS REPLICATION;
CD4 LYMPHOCYTE COUNT;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
HIV;
HIV INFECTIONS;
HUMANS;
ISOQUINOLINES;
MALE;
QUINOLINES;
SAQUINAVIR;
|
|
EID: 0029644513
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/S0140-6736(95)90699-1 Document Type: Article |
|
Times cited : (194)
|
|
References (9)
|
